Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | PHASE1 | ACTIVE NOT_RECRUITING | 23 | — | — | Jul 14, 2017 | Nov 1, 2026 | Nov 19, 2024 | 1 | United States |
Safety of fixed dose as determined by DLT to determine recommended phase 2 dosing
| Arm | Type | Description |
|---|---|---|
| Participants with CLL | EXPERIMENTAL | Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL |
| Participants with MCL | EXPERIMENTAL | Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL) |
| Name | Type | Description |
|---|---|---|
| Ibrutinib | DRUG | once daily oral intake ibrutinib |
| Pembrolizumab | DRUG | 200mg IV pembrolizumab on Day 1 of each cycle |
Inclusion Criteria: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Be ³ 18 years of age on day of signing informed consent.c 3. Have measurable disease based on: 1. Lugano classification \[6\] (cohorts A,C) 2. International Workshop on CLL \[7\] (cohorts ...